BioSpace News Archive

Biomind Labs Inc. (“Biomind Labs” or the “Company”) (NEO: BMND) (OTC: BMNDF) (FSE: 3XI) is pleased to announce a Pre-Investigational New Drug (“Pre-IND”) meeting granted by the U.S. Food and Drug Administration (the “FDA”) for the Company’s new chemical entity (“NCE”) Triptax™.

DICE Therapeutics, Inc. (Nasdaq: DICE) today announced positive topline data from its Phase 1 clinical trial of DC-806, an oral small molecule antagonist of the pro-inflammatory cytokine IL-17.

BiondVax Pharmaceuticals Ltd. announced that Joshua Phillipson, BiondVax’s Director of Investor Relations, will attend and present at the LD Micro Main Event XV, an investor conference taking place October 25 to 27, 2022 in Los Angeles.

Great Bay Bio (hereinafter referred to as “GBB”) today announces the official launch of its self-developed AI-enabled site-specific integration platform for cell line development (CLD), AlfaCell®.

VigiLanz, a clinical software surveillance company, has announced the launch of a new solution that will empower researchers to accurately identify more eligible candidates for clinical trial enrollment in near real time.

ImpediMed Limited is pleased to announce the recent expansion of the use of its SOZO® Digital Health Platform at leading cancer centers dedicated to reducing the impact of lymphedema on breast cancer patients.

ScreenPro Security Inc. (CSE: SCRN) (OTCQB: SCRSF) (“ScreenPro” or the “Company”) is pleased to announce that the Company is currently providing Covid-19 testing to eleven (11) film and production companies in Canada.

Bertis Inc., a South Korean proteomics-based precision medicine technology company, announced today it has established a U.S.-based wholly-owned entity to expand the company’s global presence and primarily provide access to the growing U.S. clinical testing market.

Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, today announced preliminary results for third quarter 2022 and reiterated full year guidance.

Satellos Bioscience Inc. (TSXV: MSCL) (“Satellos” or the “Company”), a drug discovery company aimed at developing therapeutics that regenerate muscle as a new approach to treating disease conditions from muscular dystrophy to aging, announced today that Ryan Mitchell, PhD and Director of Business Development will present preliminary preclinical proof of concept data in a second rare disease